Company news
Alzamend Neuro, Inc. (NASDAQ:ALZN) news
Alzamend Neuro, Inc. news releases on 6ix. Latest, Sep 29, 2022: Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002)…
Press releases — page 2
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
September 28, 2022
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
September 21, 2022
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
July 17, 2022
Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
May 16, 2022
Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
May 4, 2022
Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
April 27, 2022
Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s
April 10, 2022
Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board
April 3, 2022
Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
March 27, 2022
Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
December 16, 2021
Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s
November 29, 2021
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease
September 29, 2021
Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease
September 12, 2021
Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’s Disease in September 2021
August 16, 2021
Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase Agreement with Digital Power Lending
August 3, 2021
Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient’s Immunological System to Combat Alzheimer’s
July 29, 2021
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Disease
July 27, 2021
Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease
July 22, 2021
Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today
July 11, 2021
Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer’s Disease
June 30, 2021
Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million
June 16, 2021
Alzamend Neuro Announces Pricing of Initial Public Offering
June 13, 2021